Journal article
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial
Abstract
BACKGROUND: Docetaxel and cabazitaxel improve overall survival compared with mitoxantrone in patients with metastatic castration-resistant prostate cancer. Custirsen (OGX011) is a second generation highly specific antisense oligonucleotide that inhibits the production of clusterin, an antiapoptotic protein that is upregulated in response to chemotherapy and that confers treatment resistance. We aimed to assess whether custirsen in combination …
Authors
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; N K; Malik Z
Journal
The Lancet Oncology, Vol. 18, No. 11, pp. 1532–1542
Publisher
Elsevier
Publication Date
November 2017
DOI
10.1016/s1470-2045(17)30605-8
ISSN
1470-2045
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalDocetaxelDose-Response Relationship, DrugDrug Administration ScheduleHumansInternationalityKaplan-Meier EstimateMaleMaximum Tolerated DoseMiddle AgedNeoplasm InvasivenessNeoplasm StagingPrednisonePrognosisProportional Hazards ModelsProspective StudiesProstatic Neoplasms, Castration-ResistantSurvival AnalysisTaxoidsThionucleotidesTomography, X-Ray ComputedTreatment Outcome